2012 Fiscal Year Final Research Report
Development of heparin-based nanoparticles with multi-functional biological properties intended for rheumatoid arthritis therapy
| Project/Area Number |
23659022
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HASHIDA Yasuhiko 京都大学, 物質-細胞統合システム拠点, 特定研究員 (30512462)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HIGUCHI Yuriko 京都大学, 大学院・薬学研究科, 助教 (40402797)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Keywords | ドラッグデリバリー |
|---|
| Research Abstract |
This study aimed to develop a nano-sized drug carrier consisting of heparin, which has a variety of biological functions, and apply it to rheumatoid arthritis therapy. First, we conjugated native heparin or partially ring-opened heparin with sphingosine. These sphingosine-heparin conjugates form a self-assembling nanoparticle in water, which has the diameter of 120-200 nm and the ζpotential of -50 to -60 mV. Although inflammatory cytokines were produced following stimulation of mouse peritoneal macrophages with lipopolysaccharides, co-presence of the sphingosine-heparin conjugates, even without any drugs, significantly reduced the cytokine production. On the other hand, sphingosine-heparin conjugates were not effective against poly I:poly C-induced TNF-α production, suggesting that the conjugates act selectively on the TLR4/NF-κB pathway. In the mouse model of type II collagen-induced arthritis, the sphingosine-heparin conjugates, especially that derived from partially ring-opened heparin, showed remarkable anti-inflammatory effects.
|
